The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): 6-month analysis results

OBJECTIVES GLP-1 RAs are first injectable therapy recommended for T2 D. Observational studies are important for understanding clinical practice. METHODS: TROPHIES is 24-month, prospective, observational study in France, Germany and Italy on T2 D patients initiating first injectable therapy with once weekly dulaglutide (DU) or once-daily liraglutide (LIRA). Patient characteristics and outcomes at 6-months and treatment patterns at day-30 and 90 were analyzed. RESULTS: 1113 DU and 1042 LIRA patients eligible for analysis. Mean(SD) HbA1c was 8.2(1.2)% and 8.3(1.3)% at baseline for DU and LIRA, and 6.9(1.1)% and 7.0(1.1)% at 6-months (mean absolute HbA1c -1.3(1.4)% change). 35.9 % DU and 31.0 % LIRA patients reached individual targets. Baseline mean weight for DU and LIRA was 95.8(21.4)kg and 97.4(21.5)kg, and mean weight change was -3.4(5.2)kg and -3.0(5.1)kg.At baseline, 15 % DU patients started 0.75 mg and 85 % started 1.5 mg. Between days 1-90, max DU dose was 1.5 mg for 90 % patients. At day90, 83 % patients were receiving 1.5 mg DU. At baseline, 81 % patients started at 0.6 mg LIRA; 17 % at 1.2mg; and 2 % at 1.8 mg. Between days 1-90, max LIRA dose was 0.6 mg for 36 % patients; 1.2 mg for 51 %; 1.8 mg for 13 %. By day90, 31 % LIRA patients increased their dose from 0.6 mg to 1.2mg; 9 % changed from 0.6 mg to reach 1.8 mg. By day30, in both arms, around 2 % patients added, and 10 % patients stopped at least one oral therapy. CONCLUSIONS: HbA1c and weight reductions are in line with known clinical trial results. Most DU patients received 1.5 mg DU. More LIRA patients received 1.2 mg or 0.6 mg than 1.8 mg LIRA.

Interessenskonflikt

Disclosures: L.E.G-P, K.B, E.H, M.O.F, S.Z-R, M.R, K.N, and H.S are full-time employees and shareholders of Eli Lilly and Company; F.G receives research support for Eli Lilly; Lifescan, Takeda is a consultant for Boehringer Ingelheim; Lifescan; Merck Sharp & Dohme; Sanofi; AstraZeneca; Medimmune; Roche Diabetes Care; and on the advisory boards for AstraZeneca; Eli Lilly; Novo Nordisk; Roche Diabetes Care; and Sanofi. B.G provides research support for Medtronic; Vitalaire; Sanofi; Eli Lilly; Novo Nordisk; is a Clinical investigator for Sanofi; Eli Lilly; NovoNordisk; GSK; BMS; AstraZeneca; Medtronic; Abbott; Roche Diagnostics; MSD; Novartis; Janssen; Boehringer Ingelheim and on the advisory boards for Sanofi; Eli Lilly; NovoNordisk; Novartis; GSK; MSD; Boehringer Ingelheim; AstraZeneca; Abbott; Medtronic; Roche Diagnostics. U.A provides research support for Eli Lilly; and is a Clinical investigator for Eli Lilly.

Elke Heitmann is employee of Lilly Deutschland GmbH and shareholder.

Publication History

Article published online:
06 May 2021